Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
The utility of full and partial agonists for the management of opioid addiction and smoking behavior has encouraged the development of dopamine partial agonist-based medications for treating monoaminergic stimulant abuse and addiction. Aripiprazole, a recently introduced atypical antipsychotic with D-sub-2 partial agonist actions, has been studied in mice, rats, and man, but its ability to attenuate abuse- and addiction-related effects of cocaine or methamphetamine remains controversial. The present studies in monkeys were conducted to further evaluate aripiprazole as a candidate medication. The effects of aripiprazole on overt behavior were first compared with those of other dopamine-related drugs. In contrast to D-sub-2 full agonists, aripiprazole did not induce self-scratching. Like D-sub-2 receptor blockers, however, aripiprazole occasioned dose-related increases in catalepsy-associated behavior that, at the highest doses, were characterized most prominently by periods of stillness and immobility. In methamphetamine-discrimination experiments, aripiprazole did not engender responding on the methamphetamine-associated lever; rather, aripiprazole antagonized the discriminative-stimulus effects of methamphetamine by shifting its dose-effect function rightward. In self-administration "choice" experiments, acute or chronic treatment with aripiprazole did not attenuate the reinforcing strength of intravenous cocaine relative to food delivery. However, like D-sub-2 full agonists, priming injections of aripiprazole prior to sessions of intravenous saline availability engendered comparable levels of responding on levers leading to food delivery and intravenous injections. The present findings indicate that agonist and antagonist effects of aripiprazole are evident under different experimental conditions and that, like D-sub-2 full agonists, aripiprazole may have limited value for treating monoaminergic stimulant abuse and addiction.
Bergman
Jack
J
Harvard Medical School-McLean Hospital, 115 Mill Street, Belmont, MA 02478-9106, USA. jbergman@hms.harvard.edu
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000068180:Aripiprazole; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D000882:Haplorhini; D006801:Humans; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use*; D017448:Receptors, Dopamine D2 / Q000819:agonists; D012646:Self Administration; D019966:Substance-Related Disorders / Q000188:drug therapy*
D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D018491:Dopamine Agonists; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D000068180:Aripiprazole